Please login to the form below

Not currently logged in
Email:
Password:

AML

This page shows the latest AML news and features for those working in and with pharma, biotech and healthcare.

FDA approves Rigel’s Rezlidhia for acute myeloid leukaemia

FDA approves Rigel’s Rezlidhia for acute myeloid leukaemia

AML is a rapidly progressing cancer of the blood and bone marrow that accounts for about 1% of all adult cancers. ... Relapsed AML affects about half of all patients who, following treatment and remission, experience a return of leukaemia cells in the

Latest news

More from news
Approximately 18 fully matching, plus 80 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    DS-8201 is central to that effort, but it’s also hoping for strong support from other pipeline drugs like quizartinib for relapsed or refractory FLT3-positive acute myeloid leukaemia (AML) –

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    population and taking the total number of new drugs for AML in the last couple of years to seven, after decades of stagnation. ... EvaluatePharma has predicted it could become a nearly $2.5bn product by 2024, providing it can also pick up approvals in

  • Digital disruption Digital disruption

    Initially AZ and Microsoft have focused acute myeloid leukaemia (AML), simulating experiments to predict how drug combinations might be used to overcome resistance to drugs that target cell signalling in AML,

  • Deal Watch December 2016 Deal Watch December 2016

    790. Tolero Pharma (US). Dainippon Sumitomo (Japan). Acquisition with milestones. Portfolio, including alvocidib, a CDK9 inhibitor with phase II completed in AML.

  • Deal Watch July 2016 Deal Watch July 2016

    Earlier this year Jazz completed its acquisition of Celator Pharmaceuticals, acquiring a late-stage product, Vyxeos, which targets AML, and the new agreement brings complementary products to Jazz's portfolio.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

  • Actinium appoints director of clinical operations Actinium appoints director of clinical operations

    Greg's direct experience in AML and significant knowledge of clinical trial management will have an immediate impact on our capabilities that we expect will add efficiency and scale to our

  • Celgene promotes Karen Browne to haematology director Celgene promotes Karen Browne to haematology director

    She then relocated to Switzerland in March 2010, taking up the role of associate director of MDS and acute myeloid leukaemia (AML), and less than two years later was promoted to ... director with responsibility for overall MDS/AML marketing across Europe.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
KVA

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....